Galapagos - About the company
Galapagos is a public company based in Mechelen (Belgium), founded in 1999 by Onno van de Stolpe. It operates as a Developer of small molecule drugs for immunology and oncology. Galapagos has raised $136M in funding. The company has 3543 active competitors, including 1224 funded and 843 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Biogen.
Company Details
Developer of small molecule drugs for immunology and oncology. The company specialized in the discovery and development of small molecule and antibody programs in cystic fibrosis, inflammation, cancer and other indications.
- Website
- www.glpg.com
- Registered Address
- General De Wittelaan L11 2800 Mechelen
Key Metrics
Founded Year
1999
Location
Mechelen, Belgium
Stage
Public
Total Funding
$136M in 21 rounds
Latest Funding Round
Investors
Ranked
187th among 3543 active competitors
Annual Revenue
€303M as on Dec 31, 2024
Employee Count
714 as on May 31, 2026
Exit Details
Public
Legal entities associated with Galapagos
Galapagos is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Galapagos CIN: 466460429 , Belgium, Active | Jun 29, 1999 | $328M (As on Dec 31, 2024) | 449 (As on Dec 31, 2021) | - |
GALAPAGOS d.o.o. CIN: 79597073630 , Croatia, Active | Feb 21, 2017 | $193K (As on Dec 31, 2024) | - |
Galapagos's IPO details
Galapagos got listed on May 13, 2015.
Click here to take a look at Galapagos's IPO in detail
Sign up to download Galapagos' company profile
Galapagos's funding and investors
Galapagos has raised a total funding of $136M over 21 rounds. Its first funding round was on 1999. Its latest funding round was a Post IPO round on Nov 01, 2019 for $*****. 1 investor participated in its latest round. Galapagos has 19 institutional investors.
Here is the list of recent funding rounds of Galapagos:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Nov 01, 2019 | 5586484 | Post IPO | 4569426 | 4272659 | 9065007 | 5916407 |
Jun 20, 2019 | 7401804 | Post IPO | 3777217 | 7346066 | 6698601 | 5763502 |
Jan 01, 2018 | 9156024 | Grant (prize money) | 3548479 | 2168972 | 2590005 |
Access funding benchmarks and valuations. Sign up today!View details of Galapagos's funding rounds and investors
Galapagos' founders and board of directors
Founder? Claim ProfileThe founders of Galapagos is Onno van de Stolpe.
Here are the details of Galapagos' key team members:
- Onno van de Stolpe: Founder & CEO of Galapagos. They are also an angel investor in 1 startup.
View details of Galapagos's Founder profiles and Board Members
Galapagos' employee count trend
Galapagos has 714 employees as of May 26. Here is Galapagos's employee count trend over the years:
Uncover Galapagos' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Galapagos's Competitors and alternates
Top competitors of Galapagos include Jazz Pharmaceuticals, BeiGene and Biogen. Here is the list of Top 10 competitors of Galapagos, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
4th |  Abcellera Biologics 2012, Vancouver (Canada), Public | AI-enabled platform for antibodies discovery | $115M | 76/100 | |
5th |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating human disease conditions | $821M | 75/100 | |
6th | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 74/100 | ||
7th | Senti Biosciences 2016, San Francisco (United States), Public | Developer of cell-based therapies for cancer treatment | $158M | 72/100 | |
8th | Blueprint Medicines 2008, Cambridge (United States), Acquired | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | 72/100 | |
9th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
10th | _1548135965397.png?devicePixelRatio=2&height=30&width=30){kind=logo} Kronos Bio 2017, San Mateo (United States), Acquired | Developer of small molecule based therapeutics for cancer treatment | $271M | 72/100 | |
187th | Developer of small molecule drugs for immunology and oncology | $136M | 61/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Galapagos's competitors? Click here to see the top ones
Galapagos's Investments and acquisitions
Galapagos has made 3 investments in companies including Terratis and Frontier Medicines. Galapagos has also acquired 3 companies including CellPoint and Abound Bio.Here is the list of investments & acquisitions:Filter this list
Filter this listDate of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Mar 03, 2025 | Investments | 2009 | ||
Feb 22, 2024 | Investments | 2018 | San Francisco (United States) | |
Jun 21, 2022 | Acquisition | 2018 | Leiden (Netherlands) |
Want to know more about where corporates are investing? Sign up today!See all acquisitions by Galapagos
News related to Galapagos
Filter this listMedia has covered Galapagos for a total of 28 events in the last 1 year, 15 of them have been about company updates and 4 about people movement.
•
•
Galapagos & Gilead Collaborate on T Cell Engager Program for Autoimmune DiseasesGlobeNewswire•Mar 31, 2026•Galapagos, Gilead
•
Gilead Sciences Nears $2B Acquisition of Ouro MedicinesThemiddlemarket•Mar 23, 2026•Ouro Medicines, Gilead, Arcellx, Galapagos and 1 other
•
Galapagos Appoints Tania Philipp as Chief Human Resources OfficerGlobeNewswire•Mar 06, 2026•Galapagos
•
Umicore - Transparency notification by Bank of America CorporationGlobeNewswire•Feb 26, 2026•Bank of America, Umicore, Sienna, Galapagos
•
Galapagos Reports Full Year 2025 Financial Results and Business UpdateGlobeNewswire•Feb 24, 2026•Galapagos
•
Galapagos Receives Transparency Notification from Bank of AmericaGlobeNewswire•Feb 17, 2026•Galapagos, Bank of America, MRPCI, NEOS and 1 other
•
•
•
Galapagos Announces Results from Studies of GLPG3667 in Dermatomyositis & LupusBenzinga•Dec 19, 2025•Galapagos
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Galapagos
Explore our recently published companies
- Nexa Banking - Charlottesville based, Unfunded company
- Northwest Missouri Credit Union - Blair based, 1904 founded, Unfunded company
- Pinellas Credit Union - United States based, Unfunded company
- BizReply - Unfunded company
- dM Solutions Pvt.Ltd - India based, Unfunded company
- Public Service Credit Union - United States based, 1916 founded, Unfunded company
